Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Roivant Sciences’ SEC documents can feel like wading into clinical trial protocol. Pipeline updates, cash-runway figures, and milestone payments are scattered across hundreds of pages—yet a single sentence can move ROIV’s share price. If you have ever asked, “Where do I find Roivant Sciences insider trading Form 4 transactions before the market reacts?” you know the challenge.
Stock Titan solves it. Our AI instantly parses every submission—whether a dense Roivant Sciences annual report 10-K simplified for pipeline strategy, a fresh Roivant Sciences quarterly earnings report 10-Q filing detailing R&D spend, or an urgent Roivant Sciences 8-K material events explained that discloses trial data. Interactive summaries highlight what matters: Phase III read-outs, collaboration revenue, and liquidity. You can even set real-time alerts for Roivant Sciences Form 4 insider transactions real-time to monitor executive sentiment.
Searching for specifics? Our coverage spans every form investors ask about: 10-K to see cash runway; 10-Q for quarter-over-quarter expense trends; 8-K for FDA designations; the Roivant Sciences proxy statement executive compensation for option grants; and the indispensable Roivant Sciences executive stock transactions Form 4 for ownership changes. Each document comes with plain-English notes—perfect for understanding Roivant Sciences SEC documents with AI and speeding due-diligence. Quickly generate a Roivant Sciences earnings report filing analysis, track disclosure history, or export data for models—no more CTRL-F marathons.
Whether you’re an analyst gauging dilution risk or a healthcare investor timing entry around data catalysts, our platform keeps every question answered and every filing at your fingertips—updated the moment it hits EDGAR.
Roivant Sciences (ROIV) – Form 3. President & Vant Chair Frank Torti has filed his initial beneficial-ownership report covering 10.27 million common shares underlying stock options. Exercise prices range from $3.85 to $13.07 with expiry dates between 2028-2032. The largest tranche is 6.03 million options at $3.85 that vest 25% on 20-Apr-2023 and monthly thereafter; all other grants are already fully vested. No non-derivative share holdings were disclosed. The filing confirms Torti’s officer status and records his equity incentives for Section 16 compliance.
Roivant Sciences (NASDAQ:ROIV) announced a new $500 million share repurchase program in addition to their previous $1.5 billion program from April 2024. The earlier program, which had $205 million remaining capacity as of March 31, 2025, has now been fully exhausted. The new repurchase program will be funded through available cash and has no expiration date.
The company maintains flexibility in executing the buyback through various methods including open market transactions, tender offers, or private negotiations. Implementation will depend on factors such as share price, market conditions, and alternative investment opportunities. The program can be suspended or discontinued at any time.
Roivant Sciences CFO Richard Pulik reported a Form 4 filing on June 28, 2025, disclosing a transaction dated June 20, 2025. The filing details the following key transaction:
- Disposed of 1,503 common shares at a price of $11.45 per share through a "net settlement" transaction (Code F)
- The transaction was related to tax withholding obligations from the vesting and settlement of previously granted RSUs
- Following the transaction, Pulik directly owns 399,056 common shares
The filing was signed by Jo Chen as Attorney-in-Fact for Richard Pulik on June 24, 2025. This routine transaction represents standard tax withholding practices for executive RSU settlements and does not indicate a discretionary sale by the insider.
FAQ
What is the current stock price of Roivant Sciences (ROIV)?
What is the market cap of Roivant Sciences (ROIV)?
